Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
Clinical trial NCT06384352 · RECRUITING
Trial details
- NCT number
- NCT06384352
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-01
- Primary completion
- 2031-06-30
- Enrollment
- 500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.